This recent transaction increases Alison Bauerlein’s holding in the company by 398.24% to a total of $3.41 million. Following Alison Bauerlein’s last INGN Buy transaction on February 10, 2016, the stock climbed by 113.9%.
Based on Inogen’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $95.29 million and quarterly net profit of $16.43 million. In comparison, last year the company earned revenue of $69.03 million and had a net profit of $7.34 million. INGN’s market cap is $3.09B and the company has a P/E ratio of 78.67. Currently, Inogen has an average volume of 255.9K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $260.33, reflecting a 87.5% upside. Starting in February 2018, INGN received 23 Buy ratings in a row. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy INGN with a $290 price target.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inogen, Inc . engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G2 system, and Inogen at Home. The company was founded by Alison Perry, Alison Bauerlein, Brenton Taylor and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.